Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab + Erlotinib in EGFR Wild-type NSCLC
NCT02134015Phase 3Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2014
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of patritumab in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2014; status: terminated.
02
Drugs
patritumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02134015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134015.